Common Stock, par value $0.00001 per share

Galecto, Inc.

75 State Street, Suite 100, Boston, MA, 02109

Novo Holdings A/S beneficially owns no securities of the Issuer.

Novo Holdings A/S is a Danish corporation wholly owned by the Novo Nordisk Foundation. Novo Holdings A/S has the sole power to vote and dispose of the Novo Shares. Neither the Foundation nor any person listed on the updated Schedule I has the power to direct the vote as to, or the disposition of the Novo Shares.

Except as described below, Novo Holdings A/S has not effected any transactions in the Issuer's Common Stock since the most recent amendment to this Schedule 13D/A. On October 7, 2025, Novo Holdings A/S sold the following shares of Common Stock in open market transactions: - 46,562 shares at prices ranging from $16.40 to $17.355 per share (a weighted-average price of $17.02 per share); - 13,611 shares at prices ranging from $17.51 to $18.25 per share (a weighted-average price of $17.80 per share); - 6,353 shares at prices ranging from $18.69 to $19.675 per share (a weighted-average price of $19.23 per share); - 8,635 shares at prices ranging from $19.705 to $20.70 per share (a weighted-average price of $20.32 per share); - 10,318 shares at prices ranging from $20.705 to $21.49 per share (a weighted-average price of $21.04 per share); and - 1,100 shares at prices ranging from $21.81 to $21.88 per share (a weighted-average price of $21.83 per share).

Novo Holdings A/S does not know of any other person having the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, the Novo Shares.

The Reporting Persons ceased to be the beneficial owners of more than five percent of the Common Stock on October 7, 2025.